Full Text Journal Articles by
Author Scott E Eggener

Advertisement

Find full text journal articles






Editorial Comment.

Scott E Eggener,

J Urol (The Journal of urology)
[2021, :101097JU000000000000184501]

Cited: 0 times

View full text PDF listing >>



Pathological characteristics of the large renal mass: potential implication for clinical role of renal biopsy.

Aeen M Asghar, Andrew G McIntosh, Zachary L Smith, Neil J Kocher, Ziho Lee, Nimrod N Barashi, Tianyu Li, Jay D Raman, Scott E Eggener, Robert G Uzzo, Alexander Kutikov,

<h4>Introduction</h4>To assess whether patients with a large renal mass, treated by radical nephrectomy (RN), could have benefited from preoperative renal mass biopsy (RMB). The decision to perform partial nephrectomy (PN) for an organ-confined > 4 cm renal mass can be complex. Albeit often feasible, oncologic safety of PN in this ... Read more >>

Can J Urol (The Canadian journal of urology)
[2021, 28(2):10620-10624]

Cited: 0 times

View full text PDF listing >>



Advertisement

Should Grade Group 1 (GG1) be called cancer?

Craig V Labbate, Gladell P Paner, Scott E Eggener,

<h4>Introduction</h4>ISUP Grade Group 1 prostate cancer is the lowest histologic grade of prostate cancer with a clinically indolent course. Removal of the term 'cancer' has been proposed and has historical precedent both in urothelial and thyroid carcinoma.<h4>Methods</h4>Evidence-based review identifying arguments for and against Grade Group 1 being referred to as ... Read more >>

World J Urol (World journal of urology)
[2021, :]

Cited: 0 times

View full text PDF listing >>



Re: Pretransplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement.

Scott E Eggener, Piyush K Agarwal,

Eur Urol (European urology)
[2021, 79(4):552-553]

Cited: 0 times

View full text PDF listing >>



Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis.

Zhuqing Shi, Elizabeth A Platz, Jun Wei, Rong Na, Richard J Fantus, Chi-Hsiung Wang, Scott E Eggener, Peter J Hulick, David Duggan, S Lilly Zheng, Kathleen A Cooney, William B Isaacs, Brian T Helfand, Jianfeng Xu,

<h4>Background</h4>Single nucleotide polymorphism-based genetic risk score (GRS) has been developed and validated for prostate cancer (PCa) risk assessment. As GRS is population standardized, its value can be interpreted as a relative risk to the general population.<h4>Objective</h4>To compare the performance of GRS with two guideline-recommended inherited risk measures, family history (FH) ... Read more >>

Eur Urol (European urology)
[2021, 79(3):419-426]

Cited: 1 time

View full text PDF listing >>



Prostate Cancer Outcomes Following Solid-Organ Transplantation: A SEER-Medicare Analysis.

Stanley L Liauw, Sandra A Ham, Lauren C Das, Sonali Rudra, Vignesh T Packiam, Matthew Koshy, Ralph R Weichselbaum, Yolanda T Becker, Adam S Bodzin, Scott E Eggener,

<h4>Background</h4>Immunosuppressive regimens associated with organ transplantation increase the risk of developing cancer. Transplant candidates and recipients with prostate cancer are often treated, even if low-risk features would ordinarily justify active surveillance.<h4>Methods</h4>Using SEER-Medicare, we identified 163 676 men aged 66 years and older diagnosed with nonmetastatic prostate cancer. History of solid organ ... Read more >>

J Natl Cancer Inst (Journal of the National Cancer Institute)
[2020, 112(8):847-854]

Cited: 1 time

View full text PDF listing >>



Prostate-specific Antigen to Predict Early Success of Focal Therapy: Focusing on Appropriate Endpoints.

Parth K Modi, Scott E Eggener,

Eur Urol (European urology)
[2020, 78(2):161-162]

Cited: 0 times

View full text PDF listing >>



National management trends in clinical stage IIA nonseminomatous germ cell tumor (NSGCT) and opportunities to avoid dual therapy.

Craig V Labbate, Ryan P Werntz, Logan B Galansky, Vignesh T Packiam, Scott E Eggener,

<h4>Introduction</h4>For marker-negative clinical stage (CS) IIA nonseminomatous germ cell tumor (NSGCT), National Comprehensive Cancer Network and American Urological Association guidelines recommend either retroperitoneal lymph node dissection (RPLND) or induction chemotherapy. The goal is cure with one form of therapy. We evaluated national practice patterns in the management of CSIIA NSGCT ... Read more >>

Urol Oncol (Urologic oncology)
[2020, 38(8):687.e13-687.e18]

Cited: 0 times

View full text PDF listing >>



Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline Summary.

Scott E Eggener, R Bryan Rumble, Himisha Beltran,

JCO Oncol Pract (JCO oncology practice)
[2020, 16(6):340-343]

Cited: 1 time

View full text PDF listing >>



Defining risk of micrometastatic disease and tumor recurrence in patients with stage I testicular germ cell tumors.

Ryan P Werntz, Scott E Eggener,

There is controversy in the management of patients with clinical stage I non-seminomatous germ cell tumor (NSGCT). Some experts recommend surveillance for all patients regardless of risk factors while others suggest a more risk-adapted approach by using lymphovascular invasion (LVI) and the embryonal component in the primary tumor to select ... Read more >>

Transl Androl Urol (Translational andrology and urology)
[2020, 9(Suppl 1):S31-S35]

Cited: 1 time

View full text PDF listing >>



Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline.

Scott E Eggener, R Bryan Rumble, Andrew J Armstrong, Todd M Morgan, Tony Crispino, Philip Cornford, Theodorus van der Kwast, David J Grignon, Alex J Rai, Neeraj Agarwal, Eric A Klein, Robert B Den, Himisha Beltran,

<h4>Purpose</h4>This guideline provides recommendations for available tissue-based prostate cancer biomarkers geared toward patient selection for active surveillance, identification of clinically significant disease, choice of postprostatectomy adjuvant versus salvage radiotherapy, and to address emerging questions such as the relative value of tissue biomarkers compared with magnetic resonance imaging.<h4>Methods</h4>An ASCO multidisciplinary Expert ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2020, 38(13):1474-1494]

Cited: 13 times

View full text PDF listing >>



Recognizing and minimizing bias: Helping patients make their best choice for prostate cancer management through multidisciplinary clinics.

Scott E Eggener,

Cancer (Cancer)
[2020, 126(3):470-472]

Cited: 0 times

View full text PDF listing >>



Reply by Authors.

Michael D Gross, Art Sedrakyan, Fernando J Bianco, Peter R Carroll, Timothy J Daskivich, Scott E Eggener, Behfar Ehdaie, Benjamin Fisher, Michael A Gorin, Bradley Hunt, Hongying Jiang, Eric A Klein, Danica Marinac-Dabic, Jeffrey S Montgomery, Thomas J Polascik, Alan M Priester, Ardeshir R Rastinehad, Charles J Viviano, James S Wysock, Jim C Hu,

J Urol (The Journal of urology)
[2019, 202(5):958]

Cited: 0 times

View full text PDF listing >>



SPARED Collaboration: Patient Selection for Partial Gland Ablation in Men with Localized Prostate Cancer.

Michael D Gross, Art Sedrakyan, Fernando J Bianco, Peter R Carroll, Timothy J Daskivich, Scott E Eggener, Behfar Ehdaie, Benjamin Fisher, Michael A Gorin, Bradley Hunt, Hongying Jiang, Eric A Klein, Danica Marinac-Dabic, Jeffrey S Montgomery, Thomas J Polascik, Alan M Priester, Ardeshir R Rastinehad, Charles J Viviano, James S Wysock, Jim C Hu,

<h4>Purpose</h4>The SPARED CRN (Study of Prostate Ablation Related Energy Devices Coordinated Registry Network) is a private-public partnership between academic and community urologists, the FDA (U.S. Food and Drug Administration), the Medical Device Epidemiology Network and device manufacturers to examine the safety and effectiveness of technologies for partial gland ablation in ... Read more >>

J Urol (The Journal of urology)
[2019, 202(5):952-958]

Cited: 0 times

View full text PDF listing >>



Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline.

Andrew Stephenson, Scott E Eggener, Eric B Bass, David M Chelnick, Siamak Daneshmand, Darren Feldman, Timothy Gilligan, Jose A Karam, Bradley Leibovich, Stanley L Liauw, Timothy A Masterson, Joshua J Meeks, Phillip M Pierorazio, Ritu Sharma, Joel Sheinfeld,

<h4>Purpose</h4>Testis cancer is the most common solid malignancy in young males. The purpose of this guideline is to provide a useful reference on the effective evidence-based treatment of early stage testicular cancer.<h4>Methods</h4>The systematic review utilized to inform this guideline was conducted by a methodology team at the Johns Hopkins University ... Read more >>

J Urol (The Journal of urology)
[2019, 202(2):272-281]

Cited: 8 times

View full text PDF listing >>



Lymph node count impacts survival following post-chemotherapy retroperitoneal lymphadenectomy for non-seminomatous testicular cancer: a population-based analysis.

Raj R Bhanvadia, Joseph Rodriguez, Aditya Bagrodia, Scott E Eggener,

<h4>Objective</h4>To evaluate the prognostic significance of lymph node count (LNC) at post-chemotherapy retroperitoneal lymphadenectomy (PC-RPLND) in metastatic non-seminomatous germ cell tumour (NSGCT) using the Surveillance, Epidemiology, and End Results (SEER) database and National Cancer Database (NCDB).<h4>Patients and methods</h4>SEER (2000-2013, n = 572) and NCDB (2004-2013, n = 731) identified patients undergoing PC-RPLND for Stage ... Read more >>

BJU Int (BJU international)
[2019, 124(5):792-800]

Cited: 1 time

View full text PDF listing >>



The State of the Science on Prostate Cancer Biomarkers: The San Francisco Consensus Statement.

Matthew R Cooperberg, Peter R Carroll, Marc A Dall'Era, Benjamin J Davies, John W Davis, Scott E Eggener, Felix Y Feng, Daniel W Lin, Todd M Morgan, Alicia K Morgans, Daniel E Spratt, Samir S Taneja, David F Penson,

We convened a multidisciplinary expert panel to make recommendations on current utility and future research needs for post-diagnosis prostate cancer biomarkers. The San Francisco Consensus Statement reflects on the rapid recent progress achieved, and the substantial work still ahead. ... Read more >>

Eur Urol (European urology)
[2019, 76(3):268-272]

Cited: 6 times

View full text PDF listing >>



Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.

Adil S Akthar, Chuanhong Liao, Scott E Eggener, Stanley L Liauw,

BACKGROUND:Limited long-term data characterize patient-reported quality of life (QOL) following postprostatectomy intensity-modulated radiation therapy (PPRT), and predictors of decline are poorly defined. OBJECTIVE:To identify modifiable dosimetric and clinical risk factors impacting QOL and late toxicity following PPRT. DESIGN, SETTING, AND PARTICIPANTS:A prospective cohort study of consecutive men with prostate cancer ... Read more >>

Eur Urol (European urology)
[2019, 76(5):686-692]

Cited: 2 times

View full text PDF listing >>



International and Multi-institutional Assessment of Factors Associated With Performance and Quality of Lymph Node Dissection During Radical Nephrectomy.

E Charles Osterberg, Shay Golan, M Pilar Laguna Pes, Scott E Eggener, Bogdan Petrut, Shrawan K Singh, Petros Sountoulides, Levent N Türkeri, J Stuart Wolf,

<h4>Objective</h4>To determine factors associated with performance and quality of lymph node dissection during radical nephrectomy.<h4>Materials and methods</h4>Using an International Data Registry, we performed multilevel logistic regression to determine the association of surgical approach (open surgery vs minimally invasive surgery), institutional experience (low, moderate, and high tertiles), and institutional preference (minimally ... Read more >>

Urology (Urology)
[2019, 129:132-138]

Cited: 0 times

View full text PDF listing >>



The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER?

Hiten D Patel, Maneka Puligandla, Brian M Shuch, Bradley C Leibovich, Anil Kapoor, Viraj A Master, Charles G Drake, Daniel Yc Heng, Primo N Lara, Toni K Choueiri, Deborah Maskens, Eric A Singer, Scott E Eggener, Robert S Svatek, Walter M Stadler, Suzanne Cole, Sabina Signoretti, Rajan T Gupta, Marc Dror Michaelson, David F McDermott, David Cella, Lynne I Wagner, Naomi B Haas, Michael A Carducci, Lauren C Harshman, Mohamad E Allaf,

Patients with high-risk renal cell carcinoma (RCC) experience high rates of recurrence despite definitive surgical resection. Recent trials of adjuvant tyrosine kinase inhibitor therapy have provided conflicting efficacy results at the cost of significant adverse events. PD-1 blockade via monoclonal antibodies has emerged as an effective disease-modifying treatment for metastatic ... Read more >>

Future Oncol (Future oncology (London, England))
[2019, 15(15):1683-1695]

Cited: 4 times

View full text PDF listing >>



Re: Use of Active Surveillance or Watchful Waiting for Low-risk Prostate Cancer and Management Trends Across Risk Groups in the United States 2010-2015.

Ryan P Werntz, Scott E Eggener,

Eur Urol (European urology)
[2019, 76(2):252]

Cited: 0 times

View full text PDF listing >>



Multi-institutional Clinical Tool for Predicting High-risk Lesions on 3Tesla Multiparametric Prostate Magnetic Resonance Imaging.

Matthew Truong, Janet E Baack Kukreja, Soroush Rais-Bahrami, Nimrod S Barashi, Bokai Wang, Zachary Nuffer, Ji Hae Park, Khoa Lam, Thomas P Frye, Jeffrey W Nix, John V Thomas, Changyong Feng, Brian F Chapin, John W Davis, Gary Hollenberg, Aytekin Oto, Scott E Eggener, Jean V Joseph, Eric Weinberg, Edward M Messing,

<h4>Background</h4>Multiparametric magnetic resonance imaging (mpMRI) for prostate cancer detection without careful patient selection may lead to excessive resource utilization and costs.<h4>Objective</h4>To develop and validate a clinical tool for predicting the presence of high-risk lesions on mpMRI.<h4>Design, setting, and participants</h4>Four tertiary care centers were included in this retrospective and prospective study ... Read more >>

Eur Urol Oncol (European urology oncology)
[2019, 2(3):257-264]

Cited: 1 time

View full text PDF listing >>



Region-specific microRNA signatures in the human epididymis.

James A Browne, Shih-Hsing Leir, Scott E Eggener, Ann Harris,

The epithelium of the human epididymis maintains an appropriate luminal environment for sperm maturation that is essential for male fertility. Regional expression of small noncoding RNAs such as microRNAs contributes to segment-specific gene expression and differentiated functions. MicroRNA profiles were reported in human epididymal tissues but not specifically in the ... Read more >>

Asian J Androl (Asian journal of andrology)
[2018, 20(6):539-544]

Cited: 3 times

View full text PDF listing >>



Evaluation of Focal Laser Ablation of Prostate Cancer Using High Spectral and Spatial Resolution Imaging: A Pilot Study.

Shiyang Wang, Xiaobing Fan, Ambereen Yousuf, Scott E Eggener, Gregory Karczmar, Aytekin Oto,

<h4>Background</h4>Focal laser ablation (FLA) is a minimally invasive thermal ablation, guided by MRI through an optical fiber, to induce coagulative necrosis in cancer.<h4>Purpose</h4>To evaluate the feasibility of high spectral and spatial resolution imaging using multiecho gradient echo (MEGE) MRI for identification of ablation zones, after FLA of prostate cancers.<h4>Study type</h4>Prospective.<h4>Population</h4>Fourteen ... Read more >>

J Magn Reson Imaging (Journal of magnetic resonance imaging : JMRI)
[2019, 49(5):1374-1380]

Cited: 0 times

View full text PDF listing >>



Indications, evolving technique, and early outcomes with robotic retroperitoneal lymph node dissection.

Ryan P Werntz, Shane M Pearce, Scott E Eggener,

<h4>Purpose of review</h4>Examine and discuss indications, technique, and outcomes for robotic retroperitoneal lymph node dissection (RPLND) for testicular cancer.<h4>Recent findings</h4>Open RPLND has been the longstanding standard of care for both primary and post chemotherapy RPLND. Recently, robotic RPLND has been an attractive option with the intent of reducing the morbidity ... Read more >>

Curr Opin Urol (Current opinion in urology)
[2018, 28(5):461-468]

Cited: 3 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0243 s